STAT+: Drug shortages reached a record high as 2023 drew to a close
The number of ongoing and active drug shortages in the U.S. stood at 323 during…
Category: Pharmaceuticals
AskBio CSO steps down, has new project in stealth mode
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Pfizer’s plot to win the RSV vaccine race
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: FDA agrees to review a rare disease drug that its developer was about to give up on
File this under “Not a moment too soon.” After years of back-and-forth deliberations, the U.S….
Opinion: The time has come for over-the-counter antidepressants
Anyone can now walk into a pharmacy in the United States and buy oral contraceptives…
Sanofi resolves most Zantac litigation
Want to stay on top of the science and politics driving biotech today? Sign up to get…
How resurrecting extinct species might impact medicine
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Parkinson’s disease may be helped by GLP-1 drug, new study finds
The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective…
New data on liquid biopsy for colorectal cancer detection still underwhelms
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Lawmakers want to add more Chinese biotechs to defense list
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
STAT+: The biotech scoreboard for the second quarter: 32 stock-moving events to watch
Here is STAT’s biotech scoreboard, our regular ledger of stock-moving biotech events, for the second…
STAT+: Otsuka’s digital treatment for depression cleared by FDA, as pharma tries to crack tricky market
The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder,…
Aardvark Therapeutics gearing up for $200 million IPO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
What’s Congress going to do with WuXi?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Payments by drug and device makers to doctors remain widespread, but also vary considerably
The financial ties between drug and device makers and some physicians remains pervasive, despite concerns…
How GLP-1’s moved from research labs to national TV
Today is the inaugural publishing day for Adam’s Biotech Scorecard — a subscriber-only newsletter offering…
Who can sue the FDA? Answering Justice Alito’s question from the mifepristone arguments
WASHINGTON — Supreme Court Justice Samuel Alito had a clear question at Tuesday’s arguments over…
STAT+: Roche subsidiary Foundation Medicine opens new headquarters in Boston
Contemporary paintings by artists who have overcome homelessness or disabilities greet visitors in the lobby….
STAT+: European antitrust regulators probe Zoetis over pain drug for dogs
The European Commission has opened a formal antitrust investigation to determine whether Zoetis, one of…
Merck’s next big thing is (probably) on the way
New biotech newsletter launching this Thursday. Don’t miss out. Hello, everyone. Damian here with a look…
How will the Supreme Court’s mifepristone decision impact biopharma?
New biotech newsletter launching this Thursday. Don’t miss out. Hey there. Today, we discuss the…
STAT+: Novo Nordisk to acquire heart-disease focused Cardior Pharmaceuticals in deal worth $1.1 billion
LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in…
SCOTUS’ abortion pill mifepristone case is really about the FDA
WASHINGTON — The Supreme Court on Tuesday will hear opening arguments in an abortion medication…
STAT+: How biotech investors spot opportunity when stocks are down — and up
Following a blockbuster year of dealmaking and a recent uptick in biotech stocks, top investors…
EU adviser says Illumina merger was not problematic
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Drug development was once a marathon. New tools and timelines are turning it into a sprint
Drug development is more of a sprint than a marathon these days, thanks to more…
Top U.S. addiction researcher calls GLP-1 data for addiction ‘very, very exciting’
Early data regarding the use of GLP-1 medications like Ozempic and Wegovy to treat addiction…
STAT+: Regeneron’s plot to ‘cure’ allergies
George Yancopoulos is in touch with his teenage self. After 35 years as head scientist…
BioNTech is having its Pfizer moment
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharma companies and their allies seek to exempt orphan drugs from state pricing limits
As more states create dedicated boards to cap the costs of medicines, some drugmakers and…
STAT+: A preview of Intra-Cellular Therapies’ depression drug, and sizing up the MASH opportunity
I am one week away from the launch of my weekly email newsletter! It’s called…
STAT+: Medicare expected to negotiate obesity drug prices soon, new analysis predicts
WASHINGTON — Medicare will likely choose the obesity drug semaglutide for price negotiation “within the…
Novo is building a really big computer
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: J&J sues former employee for allegedly taking thousands of documents to a new job at Pfizer
Johnson & Johnson has accused a long-standing employee of taking thousands of confidential files about…
STAT+: As targeted radiation field heats up, AstraZeneca to pick up Fusion Pharmaceuticals in $2 billion deal
LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more…
Contineum Therapeutics files for IPO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’
The biggest enticement that large pharmacy benefit managers offer to the employers that hire them…
STAT+: The Boston area built a ton of lab space. Now many of those buildings are opening empty
Around this time three years ago, while most of us navigated pandemic life, real estate developers…
What happens when an approved drug doesn’t work?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline
German pharmaceutical company Bayer is expanding its U.S. pharma business significantly, despite corporate turmoil and…
Is CAR-T safe for early-stage patients?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: AstraZeneca picks up rare-disease focused Amolyt Pharma in $1 billion deal
LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal…
Geron’s resurgence might have been short-lived
Want to stay on top of the science and politics driving biotech today? Sign up to get…
When did Wall Street sour on Lilly’s Alzheimer’s drug?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Acadia’s Nuplazid fails as treatment for schizophrenia in Phase 3 study
Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social…
Preventing the weaponization of AI-designed proteins
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
STAT+: Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next
The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians,…
Eli Lilly’s anti-vanity ad campaign for Oscars
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biden’s SOTU highlights pharma’s biggest political problem: It is terrifyingly, awfully alone
If you’re a drug company executive, you probably feel like you got up on the…
STAT+: Pharma giants, government spar in court over Medicare drug price negotiation
TRENTON, N.J. — Pharma industry giants including Bristol Myers Squibb, Johnson and Johnson, Novartis, and…